|Articles|June 1, 2004
Managing risk of pregnancy
The teratogenicity of isotretinoin has been known since isotretinoin was first introduced for acne treatment. Because of this, Patricia Farris, M.D., a dermatologist based in Metairie, La., not only insists on adequate birth control use but adds that the patient must be open to the possibility that if her birth control fails that she would terminate the pregnancy.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Global Hidradenitis Suppurativa Atlas (GHiSA) Finds HS Affects 1% of the World's Population
2
Transformative Advances This Year and Beyond
3
Top 5 Articles of the Week: December 7-12
4
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
5














